You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 89 No. 1, JANUARY 1952 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

PROBLEMS OF CATION-EXCHANGE-RESIN THERAPY

S. FRIEDMAN, M.D.

AMA Arch Intern Med. 1952;89(1):99-106.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RESTRICTION of sodium intake in the form of a salt-poor diet has become an accepted form of therapy for various disease entities. These include particularly congestive heart failure, attacks of pulmonary edema, the nephrotic syndrome, and hepatic disease with ascites.

It is no easy task to prepare a varied and palatable diet which contains only 1 to 2 gm. of sodium chloride. Few patients will tolerate the monotonous, tasteless low-sodium diet for more than brief intervals. Any means which would permit these patients to ingest a diet containing a reasonable amount of sodium chloride, and yet enable them to excrete the ingested sodium without difficulty, would be a welcome solution to this problem. The use of cation-exchange resins has been suggested as a method of accomplishing this.

In 1946 Dock fed a hydrogen-cation exchanger to rats to obtain sodium depletion.1 In 1947 Gilwood suggested the use of an ammonium . . . [Full Text PDF of this Article]


Author Affiliations

BROOKLYN

From the Department of Medicine, The Jewish Hospital of Brooklyn, and The Jewish Sanitarium and Hospital for Chronic Diseases.


Footnotes

Permutit® Z (WIN 3000) was supplied through the courtesy of The Permutit Company, New York 18, and Winthrop-Stearns, Inc., New York 13.

Clinical material for this study was made available by the Departments of Medicine and Pediatrics of The Jewish Hospital of Brooklyn and the Jewish Sanitarium and Hospital for Chronic Diseases.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1952 American Medical Association. All Rights Reserved.